Trial Profile
A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Behcet's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms RELIEF
- Sponsors Amgen; Celgene Corporation
- 09 Nov 2021 Results of subgroup analysis assessing consistency of efficacy of apremilast in men and women presented at the ACR Convergence 2021
- 01 Sep 2021 Results of extension phase study assessing long-term outcomes over 68 weeks from this trial published in the Clinical and Experimental Rheumatology
- 05 Jun 2021 Results evaluating the consistency of efficacy with APR in men and women to treat oral ulcers (OU) associated with Behcet's syndrome presented at the 22nd Annual Congress of the European League Against Rheumatism